| abstract |
Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5 alpha -reductase inhibitor, e.g. a 17 beta -substituted 4-azasteroid, a 17 beta -substituted non-azasteroid, 17 beta -acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, orthothioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an alpha 1-adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed. |